Vigil Neuroscience (NASDAQ:VIGL) Receives Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Vigil Neuroscience (NASDAQ:VIGL) in a research note released on Wednesday, Benzinga reports. HC Wainwright currently has a $24.00 price target on the stock.

Separately, Morgan Stanley downgraded shares of Vigil Neuroscience from an equal weight rating to an underweight rating and lowered their price objective for the stock from $13.00 to $4.00 in a research report on Tuesday, December 19th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of Moderate Buy and a consensus target price of $17.40.

Vigil Neuroscience Stock Performance

NASDAQ VIGL opened at $3.20 on Wednesday. The business has a 50 day simple moving average of $3.06 and a 200 day simple moving average of $4.32. Vigil Neuroscience has a 52-week low of $2.53 and a 52-week high of $11.11. The stock has a market cap of $114.82 million, a price-to-earnings ratio of -1.57 and a beta of 1.80.

Hedge Funds Weigh In On Vigil Neuroscience

A number of large investors have recently bought and sold shares of VIGL. BlackRock Inc. boosted its holdings in Vigil Neuroscience by 704.7% during the second quarter. BlackRock Inc. now owns 821,452 shares of the company’s stock worth $7,722,000 after purchasing an additional 719,366 shares during the last quarter. Sphera Funds Management LTD. acquired a new stake in shares of Vigil Neuroscience in the fourth quarter valued at approximately $1,809,000. Rock Springs Capital Management LP bought a new position in shares of Vigil Neuroscience during the 1st quarter worth approximately $3,318,000. Vanguard Group Inc. bought a new stake in Vigil Neuroscience in the 1st quarter valued at $2,708,000. Finally, State Street Corp lifted its holdings in Vigil Neuroscience by 626.7% during the 2nd quarter. State Street Corp now owns 259,699 shares of the company’s stock valued at $2,441,000 after purchasing an additional 223,960 shares during the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101, a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 proof-of-concept trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.